TransMedics Group, Inc.

TransMedics Group, Inc.

TMDX·NASDAQ

$69.69

+3.2%
HealthcareMedical - Devices

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

At a Glance

Live Snapshot
Market Cap$2.41B
EPS5.6000
P/E Ratio12.44
Earnings Date07/29/2026

tmdx

Operating Cash Flow

Last Annual Value

192.84M

3-Year CAGR

84%

5-Year CAGR

53%

10-Year CAGR

26%

TransMedics Group, Inc.

TransMedics Group, Inc. Competitors Analysis of Operating Cash Flow

TMDX · NASDAQ
CompanyOperating Cash Flow
CAGR 3Y
CAGR 5Y
CAGR 10Y
192.84M
N/AN/AN/A 
-230.11M
N/AN/AN/A
-46.34M
N/AN/AN/A
134.10M
-27.4%-13.8%0.2%
171.44M
N/AN/AN/A
-232.89M
N/AN/AN/A
-27.00M
N/AN/AN/A
-147.78M
N/AN/AN/A
1.09B
N/AN/AN/A
258.45M
-11.4%4.4%N/A
IMVT logo
Immunovant, Inc.
NASDAQ:IMVT
-407.31M
N/AN/AN/A
TransMedics Group, Inc.

TransMedics Group, Inc. Fair Value Envelope

TMDX · NASDAQ

Our analysis suggests that TMDX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $69.69, this represents a potential HIDDEN relative to our calculated worth for TransMedics Group, Inc..

Intrinsic Value
Current Price: $69.69